

Please note: translation is provided for informational purposes only.

**UPDATE TO THE DECLARATION OF COMPLIANCE DATED OCTOBER 2016  
WITH THE GERMAN CORPORATE GOVERNANCE CODE PURSUANT TO SECTION 161 PARAGRAH 1  
OF THE GERMAN STOCK CORPORATION ACT (AKTG)**

.....

The Executive Board and the Supervisory Board of Epigenomics AG have issued their last Declaration of Compliance in October 2016. Owing to the occurrence of a further deviation from the recommendations under the German Corporate Governance Code (the "Code") in its version of May 5, 2015 (published by the Ministry of Justice in the official part of the Federal Gazette on June 12, 2015) respectively in its version of February 7, 2017 (published by the Ministry of Justice in the official part of the Federal Gazette on April 24, 2017), the following update of the Declaration of Compliance dated October 2016 has become necessary:

**Section 7.1.2**

Due to strategic and operational reasons the Consolidated Financial Statements for the financial year 2016 have been published on April 26, 2017 only. Accordingly, in deviation from the recommendation pursuant to Section 7.1.2 of the Code, the Consolidated Financial Statements for the financial year 2016 have not been made publicly accessible within 90 days of the end of the financial year. Regarding future financial years the Company will again comply with the recommendation pursuant to Section 7.1.2 of the Code.

Berlin, April 2017

**On behalf of the Supervisory Board:**

**On behalf of the Executive Board:**

Heino von Prondzynski  
(Chairman of the Supervisory Board)

Gregory K. Hamilton  
(CEO)

Dr. Uwe Staub  
(COO)